Eli Lilly disclosed additional safety and tolerability data for retatrutide at the American Diabetes Association meeting, including counts of arrhythmias and major cardiovascular complications versus placebo. The new dataset was presented as part of ongoing TRANSCEND-T2D-1 updates and was published in The Lancet, continuing to sharpen the risk-benefit profile for the next-generation obesity drug.